The Next Wave of LISTs for BPH: How Much Is Innovation, How Much Is Hype

ICUA Viewpoint · Innovation & BPH

The second generation of LISTs is no longer selling only “less invasiveness”. It is selling anatomy-tailored care, better functional preservation, and a friendlier overall treatment experience. The real question is how much of that promise will translate into meaningful patient benefit and how much is simply a better narrative.

The field of minimally invasive treatment for BPH is entering a second phase.

The first phase was defined by the consolidation of recognizable names: UroLift, Rezūm, iTIND, PAE, Aquablation. Each had a relatively clear value proposition, a plausible niche, and a progressively identifiable evidence base.

The second phase is different.

New generations of devices and concepts are now appearing with a more ambitious promise: lower treatment burden, better anatomical adaptation, better sexual preservation, lower perioperative disruption, and an overall more acceptable patient experience.

That sounds appealing. And part of it may prove to be true.

But it is also exactly the kind of territory where real innovation and hype can begin to look uncomfortably similar.

What the new generation is promising

The new wave of LISTs no longer wants only to be “less invasive”. It wants to be more precise, more functional, more anatomically personalized, more acceptable to surgery-averse patients, and, ideally, durable enough to avoid becoming a temporary compromise.

That is a much stronger promise than the first wave offered.

Because it is no longer just selling a procedure. It is selling a vision of the future: better treatment with less penalty and more individualization.

In both market terms and clinical storytelling, that is a very powerful proposition.

Why this evolution makes sense

It would be unfair to dismiss it outright.

The BPH field still carries several unresolved tensions: how to achieve meaningful deobstruction without imposing so much sexual penalty, how to avoid overtreatment in patients who do not want high-powered surgery, how to individualize treatment better according to anatomy and patient priorities, and how to reduce the psychological and logistical burden of intervention.

In that sense, the emergence of new technologies is not arbitrary fashion. It responds to real unmet needs.

The question is not whether there is room for innovation. The question is how much of that innovation will be clinically meaningful and how much will mainly represent an improved narrative.

The new candidates

Among the names now entering the conversation are Optilume BPH, Zenflow Spring, Butterfly, ProVee, Urocross, and FloStent.

They all belong to a second-generation storyline: lower burden, more personalization, potentially more comfort, and a stronger promise of preserving function.

That makes them interesting. But for now, in most cases, they still matter more as a signal of where the field wants to go than as fully established additions to clinical practice.

Where there may be genuine innovation

1. Better anatomical matching

Many of the shortcomings of the first wave came from applying “minimally invasive” procedures to patients or anatomies for which they were never truly ideal.

If a new generation of LISTs can genuinely improve matching according to prostate size, median lobe configuration, bladder neck anatomy, and type of obstruction, that would represent meaningful progress.

2. A better balance between function and durability

This is the deeper promise of the field.

Until now, BPH innovation has largely lived with a fracture line: the more function is preserved, the greater the risk of sacrificing deobstructive power or durability.

If any new technology can materially shift that balance, it will deserve real attention.

But that threshold is high. It is not enough to look elegant. A procedure has to prove that it changes the equation in clinically meaningful terms.

3. Lower burden without drifting into undertreatment

The challenge is not simply to do less. It is to do less without doing too little.

That is one of the central uncertainties of the entire field.

Where hype is most likely

1. “Minimally invasive” as an emotional shortcut

The label has enormous psychological force. It suggests less pain, less risk, less regret, and less disruption.

But “less invasive” does not automatically mean “better” or even “enough”. Sometimes it simply means that the therapeutic cost is displaced elsewhere: more retreatment, lower efficacy, or greater dependence on ideal anatomy.

2. Sexual preservation as the dominant storyline

Ejaculatory preservation is one of the great engines of the LIST field, and rightly so.

But it is also an easy territory for overemphasis. When a technology foregrounds sexual function almost exclusively, we should ask: what happens to durability? what happens to deobstructive power? what happens in real-world outcomes? what happens when anatomy is less than ideal?

If those questions are not answered, then the result is not truly patient-centered care. It is selective storytelling.

3. High visibility with limited maturity

This is especially relevant for several of the newer remodeling or stent-like concepts.

The fact that a device appears in reviews, meetings, or “future of BPH” conversations does not mean it has already earned a stable role in practice.

In some cases, what grows first is not the evidence base, but the expectation.

4. Highly active adoption networks

Every innovation needs clinical leaders. That is normal and often beneficial.

But the more device-driven a field becomes, the more important it is to distinguish legitimate enthusiasm from early adoption and from independent validation.

A technology may look very promising within an adoption network and still not have demonstrated a sufficiently robust, independent benefit.

The case of Optilume BPH

If one name currently deserves special attention in this second wave, it is Optilume BPH.

It is probably one of the most advanced candidates in the emerging block. It offers a clear narrative: low burden, preserved function, and an interesting hybrid therapeutic concept.

That deserves attention.

But for exactly that reason, it should be asked the same hard questions as everything else: in which anatomy does it perform best? what is its true durability? where does it sit relative to Rezūm, PUL, or iTIND? where does it sit relative to Aquablation or HoLEP? is its value mainly functional, logistical, or genuinely therapeutic?

Until those questions are answered with more maturity, the right response is interest combined with restraint.

What any new LIST should be required to prove

Before a new technique claims a stable role, it should be able to answer five questions clearly:

What anatomy is it really for?
What is the retreatment burden at meaningful follow-up?
What does it add over existing LISTs?
What does it add over Aquablation or HoLEP?
Is its main value functional, logistical, or truly therapeutic?

If it cannot answer those questions, it is probably still closer to a promise than to a standard.

So how should we read what is coming?

With curiosity, yes. But also with discipline.

Innovation in BPH care is necessary. Not everything new is smoke, and the field still needs better solutions for patients who currently feel caught between treatments that are too weak and surgeries they perceive as too aggressive.

But that is precisely why the standards should be demanding.

It is not enough for a technology to be new. It is not enough for it to be elegant. It is not enough for it to preserve ejaculation better. It is not enough for it to have a modern personalization narrative.

It has to show that it truly improves the balance between deobstruction, function, durability, and treatment burden.

Conclusion

The next wave of LISTs may bring real innovation. But it may also bring an inflation of promises.

The line between those two possibilities will not be drawn by marketing or by device sophistication. It will be drawn by a very simple question:

Does this technology add something clinically meaningful that we cannot already achieve with existing options, and does it do so without merely shifting the problem elsewhere?

Until that becomes clear, this field deserves attention—but not automatic admiration.

Because the future of LISTs will not be decided by novelty alone. It will be decided by whether they can genuinely improve patients' lives without promising more than they can deliver.

ICUA take-home message
The second generation of LISTs deserves serious attention, but not automatic enthusiasm. The relevant innovation will be the one that truly improves the balance between efficacy, function, and treatment burden—not the one that simply refines the language in which it is presented.

Dr. Fernando Gómez Sancha's English Blog

Saturday, April 18, 2026